Browsing Tag
NASDAQ
348 posts
PepsiCo (PEP) beats Q1 2026 earnings estimates as Frito-Lay volumes return to growth after price cuts
PepsiCo beat Q1 2026 estimates with $1.61 core EPS and $19.4B revenue as Frito-Lay volumes inflected. Full-year guidance affirmed. Read the full analysis.
Why Jane Street’s $7bn CoreWeave bet could reshape AI infrastructure demand in finance
Jane Street’s $6 billion CoreWeave cloud deal and $1 billion stock buy could reshape AI infrastructure demand in finance. Read the deeper strategic story.
Why is CareDx (CDNA) selling its Lab Products business to EuroBio Scientific now?
CareDx is selling its Lab Products business to EuroBio Scientific for $170 million. Read what the deal means for growth, margins, and CDNA stock.
Verra Mobility (NASDAQ: VRRM) bets on in-car ancillary sales as rental counters lose relevance
Verra Mobility launches an in-vehicle checkout tool for rental cars. Read how AutoKinex could reshape ancillary revenue and digital fleet operations.
Sidus Space (NASDAQ: SIDU) strengthens StarVault role as Lonestar scales sovereign data storage network
Sidus Space expands its Lonestar StarVault deal with a second payload order. Read why this could matter for orbital data storage and SIDU stock.
AMZN stock rises 3.8% as Amazon seals $11.6bn Globalstar acquisition to expand Amazon Leo satellite network ahead of SpaceX IPO
Amazon to acquire Globalstar for $11.6bn to add direct-to-device satellite capability to Amazon Leo and power Apple's iPhone satellite services. What it means for markets and Starlink. Read more.
Kazia Therapeutics (NASDAQ: KZIA) bets on SETDB1 to widen oncology pipeline beyond paxalisib
Kazia Therapeutics has licensed a SETDB1 oncology platform from QIMR Berghofer. Read why the move could reshape KZIA’s pipeline strategy.
Hoth Therapeutics stock jumps on HT-VA data, but can HOTH turn preclinical promise into a real metabolic pipeline?
Hoth Therapeutics says HT-VA reprogrammed liver fat metabolism and outperformed semaglutide on key markers. Read what this means for HOTH now.
TBBK is back on retail radar, but can The Bancorp prove the story in Q1?
Is The Bancorp (NASDAQ: TBBK) worth watching before April 2026 earnings? Read the catalyst, valuation, risks, and retail investor roadmap now.
Could Neurocrine’s $2.9bn Soleno deal turn VYKAT XR into its next rare-disease blockbuster?
Neurocrine is buying Soleno for $2.9 billion to add VYKAT XR. Read what the deal means for NBIX growth, rare-disease strategy, and investor sentiment.